Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

27th May 2015 by Louise Hudman

Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

This new guideline from Nice states that rivaroxaban can now be used after ACS with elevated cardiac enzymes. It should be used either with aspirin, or with aspirin and clopidogrel together.

  • It decreases the combined end points of MI, CVA or deaths from cardiovascular events by 20%.
  • There is a 3 x increased risk of major bleeding, so bleeding risk must be assessed.
  • Use beyond 12m hasn’t been studied, so use beyond that point is for clinical judgement.

It is generally started about a week after the event, so it is likely that we will be starting it, though hopefully it will be advised in the discharge summary.

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


"I have always valued real-person interactive support which the National Association of Sessional GPs has given in spades. It is particularly helpful for the older GP locums who may not be technologically savvy and may feel 'forced into' locum work at the end of their professional career when it wasn't necessarily a planned choice. "

Dr David Grant, GP, Lincolnshire

See the full list of features within our NASGP membership plans